Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Cancer Diagnostic Probe: 1. Generic Name :Cancer Diagnostic Probe
2. Brand Name(if registered under the Trade Marks Act, 1999) :Coosa
3. Notified Category :Cancer diagnostic Probe
4. Cl
a wireless electrical head probe used by the surgeon
[and] a main control
computer system which receives the signals from the head probe. It electrochemically
measures the hypoxia glycolysis metabolism in real-time in pre-cancerous and cancerous
lesion
Sponsors
Coosa Technologies Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: The following inclusion criteria will be considered for the study CDP can be used for patients of all ages and genders with breast tumor disease who are candidates for breast conserving surgery in adjuvant non neoadjuvant cases.
Exclusion criteria
Exclusion criteria: Patients with the following will be excluded from the study 1. Patients with non palpable tumor 2. Patients exhibiting post NACT complete response All patients diagnosed with breast cancer which were candidates for breast conserving surgery. All the patients will be informed about the process and sign the consent before the surgery. The patient gender, age, and surgical history, and adjuvant or neoadjuvant chemotherapy are not effective parameters for the patient recruitment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will provide the primary outcomes data In process Clinical trial observations.Timepoint: Secondary outcome data will start on after 6 Weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| To observe the results after the pathology findings.Timepoint: based on observational study data which comes after 14 weeks. | — |
Countries
India
Contacts
Public ContactDr Ashutosh Mishra
DR BRA-IRCH All India Institute of Medical Sciences, New Delhi, India
Outcome results
None listed